Page 3 - Repurchase Offer News Today

DISRUPTIVE CAPITAL ACQUISITION COMPANY LIMITED (“DCAC” or the “Company”) Release of Circular and Notice of Extraordinary...

17.11.2022 - BlackRock Enhanced Government Fund, Inc. (the “Fund”) (NYSE: EGF, CUSIP: 09255K108) announced the expiration of the Fund’s annual repurchase offer for its shares of common stock (the “Repurchase Offer”). The Repurchase Offer and withdrawal rights ... Seite 1

EQS-Ad-hoc: ZEAL Network SE / Key word(s): Share Buyback ZEAL Network SE: Public share repurchase offer for up to approximately 3.2% of the sh...

Investegate announcements from ZEAL Network SE, Public share repurchase offer for up to approximately 3.2% of the share capital

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Pratteln, Switzerland, May 4, 2021 – Santhera ...

Santhera Pharmaceuticals Holding AG: Santhera Announces Settlement of Exchange Offer and Issuance of New Senior Unsecured Convertible Bonds due 2024 Pratteln, Switzerland, s the settlement of the e . Santhera Pharmaceuticals Holding AG is settling today its offer to exchange its outstanding CHF 60 million 5% Convertible Bonds due 2022 (the 2017/22 Bonds) on the terms set out in the Notice of Repurchase Offer dated March 25, 2021 (the Exchange Offer). Upon settlement, 2017/22 Bonds in the a...

More from AP

By Notice of Repurchase Offer dated March 25, 2021 (the Notice), Santhera Pharmaceuticals Holding AG announced an offer to exchange its outstanding CHF 60 million 5% Convertible Bonds due 2022 (the 2017/22 Bonds) on the terms set out in the Notice (the Exchange Offer). The Exchange Offer was accepted by bondholders with respect to 2017/22 Bonds with an aggregate principal amount of CHF 44,845,000, corresponding to 74.7% of all 2017/22 Bonds in circulation. S ettlement Santhera has decide...

By Notice of Repurchase Offer dated March 25, 2021 (the Notice), Santhera Pharmaceuticals Holding AG announced an offer to exchange its outstanding CHF 60 million 5% Convertible Bonds due 2022 (the 2017/22 Bonds) on the terms set out in the Notice (the Exchange Offer). The Exchange Offer was accepted by bondholders with respect to 2017/22 Bonds with an aggregate principal amount of CHF 44,845,000, corresponding to 74.7% of all 2017/22 Bonds in circulation. S ettlement Santhera has decide...

Santhera Pharmaceuticals Holding AG: Santhera Reports 2020 Annual Results 4 this statement. CHF 67.7 20 as the basis for future growth S Pratteln, Switzerland, Company 20 lead uchenne muscular dystrophy (D . "Santhera started 2021 with the strong foundation of a refreshed clinical and operational strategy focused on vamorolone, which we believe can provide significant value to patients, caregivers, and ultimately shareholders. It represents the key foundation for the future of Santhera, wh...